Stock Analysis
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis
Edgewise Therapeutics, Inc. (EWTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Edgewise Therapeutics, Inc. (EWTX) currently has an AIQ Score of 72/100, indicating a bullish setup. Momentum is the strongest factor at 82/100. Risk is the weakest current factor at 57/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
EWTX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $45.93 |
| AIQ Score | 72/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $5B |
| P/E Ratio (TTM) | 4.97 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $10.71 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.1 |
| Volume | 1.16M |
| 52-week range | $19.76-$48.78 |
| RSI 14 | 61.82 |
| 50-Day SMA | $41.33 |
| 200-Day SMA | $37.01 |
| Analyst Price Target | $71.00 |
| Next Earnings | Feb 25, 2027 |
EWTXEdgewise Therapeutics, Inc.
Healthcare / Biotechnology
Leader
Sector Leader
Latest quote
- Momentum82
- Value—
- Quality68
- Risk resilience57
- Sentiment—
EWTX Stock Analysis Summary
Edgewise Therapeutics, Inc. (EWTX) currently has an AIQ Score of 72/100, indicating a bullish setup. Momentum is the strongest factor at 82/100. Risk resilience is the weakest current factor at 57/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, EWTX has AIQ Score of 72/100 with Momentum base of 82/100 and fading Risk resilience at 57/100. Wait for component alignment before adding exposure.
Momentum (82/100) leads while Risk resilience (57/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.24% stock move · EWTX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is EWTX Bullish or Bearish Right Now?
EWTX currently has a bullish overall setup. Momentum is the strongest factor at 82/100, while Risk Resilience is weakest at 57/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 68/100.
- - Momentum is constructive at 82/100.
- - Price is +11.13% above its 50-day SMA.
- - Analyst target implies +54.58% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (36 vs 4).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
EWTX's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 6 neutral, and 4 sell votes. EWTX's 14-day RSI is 61.82, which places the stock in a constructive momentum range. EWTX's beta is 1.1, indicating market sensitivity broadly in line with the market.
What Changed in EWTX?
The largest recent change in EWTX is Momentum moving up by 11.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the EWTX Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
EWTX Decision Framework
Public evidence layers, setup checks, and risk context for Edgewise Therapeutics, Inc..
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis
Edgewise Therapeutics, Inc. has an AIQ Score of 72/100 in a Bullish regime. Momentum is strongest at 82/100. Beta is 1.1, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | EWTX is in a Bullish AIQ regime with score 72/100. |
| Signal Conflict | The primary conflict is that momentum leads at 82/100 while risk lags at 57/100. |
| Factor Evidence | Momentum 82/100 · Quality 68/100 · Risk 57/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 82/100.
Momentum is 82/100 and RSI (14) is 61.8.
EWTX is in a Bullish regime at 72/100.
Risk factor is 57/100 with beta 1.1 and annual volatility 73.21%.
Current conflict: momentum leads at 82/100 while risk lags at 57/100.
EWTX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
EWTX Fundamentals
EWTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
EWTX Technical Analysis
EWTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
EWTX Stock Catalysts
Track EWTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
EWTX Dividend Analysis
EWTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
EWTX Financial Data
EWTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
EWTX Risk Analysis
EWTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
EWTX Stock News
EWTX stock news, market tone, recent headlines, and catalyst context.
EWTX vs Biotechnology Peers
Current peer cohort: EWTX · EXEL · FTRE · GMAB · HALO. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| EWTX Current stock | 72/100 | — | 82/100 | 57/100 | 1.41 | 73.21% | Current |
| EXEL Exelixis, Inc. | 82/100 | 79/100 | 91/100 | 77/100 | 1.5 | 33.90% | EWTX vs EXEL |
| FTRE Fortrea Holdings Inc. | 75/100 | 93/100 | 88/100 | 41/100 | 1.29 | 67.32% | EWTX vs FTRE |
| GMAB Genmab A/S | 77/100 | 71/100 | 94/100 | 58/100 | 1.29 | 45.85% | EWTX vs GMAB |
| HALO Halozyme Therapeutics, Inc. | 78/100 | 76/100 | 84/100 | 63/100 | 0.95 | 41.04% | EWTX vs HALO |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for EWTX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching EWTX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for EWTX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
EWTX Stock FAQ
What is EWTX stock price today?
Edgewise Therapeutics, Inc.'s current stock price is $45.93. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is EWTX bullish or bearish right now?
EWTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is EWTX's market cap?
EWTX's market cap is $5B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is EWTX's current P/E ratio?
EWTX's current P/E ratio is 4.97 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is EWTX's RSI?
EWTX's 14-day RSI is 61.82 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is EWTX above its 50-day and 200-day moving averages?
EWTX is 11.13% from its 50-day SMA and 24.11% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is EWTX's next earnings date?
EWTX's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does EWTX pay a dividend?
EWTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.